Symptom-alleviating effect and adverse effect of dienogest in Korean women with endometriosis
article
OA: closed
CC0
⤵ 4 in-corpus citations
AI-generated summary
Dienogest significantly reduced pelvic pain and improved quality of life in Korean women with endometriosis, though side effects varied with treatment duration.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The purpose was to evaluate the effects of dienogest on Korean women with endometriosis. A cross-sectional questionnaire-based survey was conducted for 100 premenopausal women. They had taken or were taking 2 mg of dienogest daily. We assessed the pelvic pain score and quality-of-life (QOL) score before and after taking dienogest as well as the prevalence of short-term (≤12 weeks) and long-term adverse effects (>52 weeks). Patients were classified into three groups: dienogest treatment immediately following surgery (A), dienogest treatment for a recurrence of endometriosis after surgery (B), or dienogest treatment without any surgery (C). In groups A and C, the median pain score (from 5 to 0, p <.001; from 7 to 1.5, p <.001) and median QOL score (from 10 to 5, p = .002; from 7.5 to 6.5, p = .008) were significantly decreased. Irregular bleeding and decreased menstrual flow were more prevalent in patients with dienogest intake of fewer than 12 weeks, while amenorrhea, weight gain, hair loss, and dorsal pain were more prevalent in patients with dienogest treatment of over 52 weeks. Accordingly, proper counseling is necessary when prescribing dienogest.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (17)
- A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis via openalex
- Clinical dynamics of Dienogest for the treatment of endometriosis: from bench to bedside via openalex
- Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive via openalex
- Dienogest via openalex
- Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
- Efficacy and safety of dienogest in patients with endometriosis: A single-center observational study over 12 months via openalex
- Menstrual symptoms in women with pelvic endometriosis via openalex
- Pharmacodynamic study of four oral dosages of dienogest via openalex
- Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest via openalex
- Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex
- Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis via openalex
- Treatment of pelvic pain associated with endometriosis via openalex
- W2045458073 via openalex
- W2079421112 via openalex
- W2101417341 via openalex
- W2615713587 via openalex
Cited by (4)
Source provenance
- europepmc
- last seen: 2026-08-02T06:10:09.037253+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:19:49.066213+00:00
License: CC0
· commercial use OK